GE HealthCare Technologies Inc. has announced a wave of transformative innovations in healthcare that will be showcased at the upcoming RSNA 2025 conference. The company highlighted its significant investment of over $3 billion in research and development since 2022, resulting in advancements across smart devices, radiopharmaceuticals, and AI-enabled solutions. GE HealthCare currently leads the industry with 100 FDA-authorized AI-enabled medical device solutions, aimed at transforming clinical workflows and supporting rapid, precise decision-making. Among its recent breakthroughs is Flyrcado, a first-of-its-kind PET molecular imaging agent for diagnosing and assessing coronary artery disease, marking a major innovation in nuclear cardiology. These results and innovations will be presented at RSNA 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251130700152) on November 30, 2025, and is solely responsible for the information contained therein.
Comments